Back to catalogue
№ 252 12 filings · 2025-10-01 → 2026-05-29

MEDPAL AI PLC

MPAL
Health Care Share price 4.35p Market cap £34m Overall fit 140 /1000

Poor fit for the strategy on all three pillars: not a genuine AI receiver (pharmacy with an AI marketing wrapper), valuation already prices significant execution, weak balance sheet with going-concern risk and ongoing dilution. Some operating leverage and genuine GLP-1 optionality prevent a sub-100 score.

Fair value range 2p–3p Mid case · £16m
Absolute upside -52.7% vs current market cap
Conviction 2/5 confidence in overvalued call
Supports the call
  • Going-concern flag and £4k cash at period end give a hard valuation anchor
  • Serial placings at falling prices (4p → 2.5p) define a market-clearing valuation below current
  • Pharmacy unit economics (34% GM, 80k items/m breakeven) provide a quantitative base case
Limits the call
  • Only one half-year of operating data; GLP-1 ramp and Runcorn reactivation are real but unquantified upside
  • Micro-cap retail-driven AIM stock with volatile narrative-driven price action
Methodology

EV/forward-revenue peer cross-check vs. path-to-breakeven sanity model

In one line · bull case

Executing GLP-1 and NHS dispensing roll-up with credible operational pathway to a doubling of run-rate revenue, anchored by direct Eli Lilly and Novo Nordisk supply agreements.

In one line · biggest risk

Going-concern-flagged balance sheet and serial sub-3p placings mean further dilution is the base case and may continue to repress per-share value even if operations scale.

Drivers
AI beneficiary 20 /100
AI is a marketing wrapper on a robotic NHS pharmacy and a third-party Vertex AI triage bot; no AI-driven revenue line capturing infrastructure spend.
Operating leverage 50 /100
Fixed dispensing infrastructure gives some leverage but 34% GM and inventory-heavy working capital are more distributor-like than SaaS-like.
Earnings vs expectations 50 /100
Not enough data — only one half-year of trading post-IPO, so default 50.
Growth momentum 82 /100
Revenue zero to £5m+ run rate in five months, with credible operational levers to push higher.
Moat 15 /100
No structural moat; NHS pharmacy is commoditised and the consumer app has no demonstrated retention or pricing power.
Earnings quality 25 /100
Heavy share-based payments, capitalised in-house IP, related-party asset transfers, and going-concern emphasis all weigh on quality.
Management quality 20 /100
Founder-CEO related-party IP and Runcorn deals, chairman exit, auditor name error, and serial down-round dilution all flag governance concerns.
Cyclicality 25 /100
NHS dispensing and chronic-condition demand are largely non-cyclical.
Leverage 45 /100
Modest reported debt but cash of £4k and recurring need for equity make the balance sheet fragile despite low leverage ratios.
Value-trap signals · 9
  • Going-concern material uncertainty in audit opinion
  • Cash of £4,189 vs. £1.06m payables at H1 close
  • Serial dilutive placings at falling prices (4p → 2.5p)
  • Founder IP sold to company for 192.5m shares
  • Founder personally acquired Runcorn rights then novated to group
  • Large share-based payments reserve relative to cash admin spend
  • Chairman resignation announced with AGM notice
  • AGM result RNS reissued due to incorrect auditor name
  • AI branding without proprietary AI revenue

MedPal AI plc (MPAL) — Research Note

Executive summary

MedPal AI is an AIM-listed UK digital health roll-up that pairs a consumer wellness app with two acquired NHS distance-selling pharmacy hubs (Swaffham, Runcorn) and a private GLP-1 weight-loss clinic, all marketed under an "AI Health OS" wrapper. Since its August 2025 IPO at 4p the operating story has progressed quickly — from pre-revenue to a £5m+ pharmacy run rate by March 2026 (>41,000 items dispensed in March, 34% gross margin) 2026-05-29 interim — but the financial story has gone the other way: a £3.27m H1 loss, just £4,189 of cash at period end, a going-concern emphasis-of-matter from the auditor, repeated dilutive placings at declining prices, and a share count that has ballooned from 46m to 616m in eighteen months. The single most important valuation point: the current £25.6m market cap capitalises a business that is still loss-making, working-capital-starved, and dependent on perpetual equity issuance, on the bet that combined dispensing volumes can re-approach the Runcorn site's pre-administration peak of ~100k items/month.

Fair value estimate

  • Fair value range: 2.0p – 3.2p per share → implied market cap £12m – £20m (vs. £25.6m today).
  • Methodology: EV/forward-revenue cross-check against UK online-pharmacy peers, sanity-checked against a simple path-to-EBITDA breakeven model. At the management-flagged 80k items/month breakeven (≈£9.3m annualised pharmacy revenue at £9.70 avg item value 2026-04-29 Remedi acquisition), and even adding the GLP-1 clinic, fair group revenue 12 months out is £10–15m. Loss-making distance-selling pharmacies trade at 0.5–1.2x sales; allowing a modest premium for GLP-1 supply agreements and the app optionality gives an EV range of £12–20m. Net debt is small but cash is essentially nil, so EV ≈ equity value.
  • Upside vs. current 4.15p price: –23% to –52% (i.e. fair-to-cheap range sits below current). Stock is overvalued on a central case; the bull case relies on Runcorn being reactivated to ≥100k items/month AND a successful GLP-1 ramp AND no further significant dilution — three sequential leaps.
  • 616m shares pre-warrants; another ~170m options/warrants outstanding 2026-05-29 interim, Note 8 would push diluted share count over 780m. On any equity raise at sub-3p, the fair-value/share number falls further.

Sector context

  • Sector confirmed: Health Care (ICB). Sub-sector: online pharmacy / digital health.
  • Profile is below typical Healthcare peers: pre-profit, going-concern-flagged, micro-cap with retail-driven trading, and a roll-up balance sheet built on share issuance rather than retained earnings.
  • Listed peers (loosely): Pharmacy2U (private), Well Pharmacy (private), NowPatient, AIM-listed Eqtec / Verici / Yourgene-style micro-cap health names. The closest reference for valuation is the broader NHS dispensing margin pool, where pharmacies routinely trade at sub-1x revenue.

Investment thesis (3 bullets)

  • GLP-1 supply agreements with both Eli Lilly (Mounjaro) and Novo Nordisk (Wegovy) are commercially scarce and position MedPal.clinic in the UK's fastest-growing private healthcare segment, with FDA approval of oral Wegovy expanding the addressable population 2026-01-05 trading update; 2026-05-29 interim.
  • Runcorn re-activation playbook is concrete: the site dispensed >100k items/month before administration in 2024; MedPal acquired it for £310k in cash and is applying the Swaffham reactivation template, putting a credible pathway to combined run-rate well above the stated 80k items/month pharmacy-EBITDA breakeven 2026-04-29 Remedi acquisition.
  • B2B care home channel (Care UK, 200+ homes) is high-retention, high-volume, providing a non-discretionary revenue floor underneath the more speculative consumer app / GLP-1 layers 2026-05-29 interim.

Key risks (3 bullets)

  • Liquidity is the binding constraint. Period-end cash of £4,189 against £1.06m trade payables 2026-05-29 interim balance sheet; the auditor flagged a material uncertainty over going concern 2026-02-27 final results, Note 22. Even after the post-period £4m raised, structural cash absorption from inventory and clinic marketing means another placing within 12 months is the base case.
  • Serial dilution at declining prices. IPO at 4p → ATM tranches at 6.6p / 6.1p / 5.2p / 5.1p → March 2026 placing at 2.5p → April 2026 £3m placing at 2.5p. The April raise alone added 120m shares (~24% of the prior share count) at a 13% discount 2026-04-17 placing. Shares outstanding have gone from 46m (Aug 2024) to 616m today (>13x).
  • Governance / related-party flags. Founder-CEO Drummond issued 192.5m shares to himself for the "MedPal IP" pre-IPO (≈47% of pre-IPO equity for an asset with then-uncertain value) 2026-02-27 final results, Note 18; the Runcorn pharmacy rights were personally bought by Drummond and novated to the company (related-party AIM transaction) 2026-04-29 Remedi; auditor RNS was issued with a wrong name and had to be replaced 2026-04-02 AGM-Replacement; chairman stepped down within days of the AGM 2026-03-09.

Operating leverage

The pharmacy is a fixed-cost dispensing operation — robotic BD Rowa / Omnicell infrastructure, GPhC governance overhead, a regulated pharmacist payroll, plus a third-of-revenue NHS gross margin — so on paper it screens as an operating-leverage story: at the stated 80k items/month break-even (~£9.3m annual revenue, ~£3.2m gross profit) the existing two-hub footprint is described as having "substantial operational headroom" 2026-04-29 Remedi acquisition. The mathematics, however, are less SaaS-like than the marketing implies. H1 admin spend was £3.36m and development costs £0.38m, against £0.37m gross profit 2026-05-29 interim. To cover the current run-rate £6.7–7.5m of annual admin + dev, the group needs combined dispensing of c.£20m+ revenue at 34% margin — i.e. closer to 170k items/month — or a meaningful uplift in mix toward higher-margin GLP-1 private revenue. So the contribution-margin profile is more like a moderately fixed-cost distributor (40–55 on this driver) than a 70%+-gross-margin platform business. The genuine long-tail leverage sits in the consumer app / Health OS layer, which currently has 7,791 installs and no disclosed revenue model.

Value-trap signals

  • Going-concern uncertainty disclosed by auditors 2026-02-27 final results.
  • Cash of £4,189 against £1.06m trade payables at H1 close 2026-05-29 interim.
  • Serial dilutive equity raises at successively lower prices (4p → 2.5p in eight months).
  • Material related-party transactions: IP sold by founder to company for shares; Runcorn acquired in founder's name then novated to group 2026-02-27; 2026-04-29.
  • Heavy share-based compensation: £3.43m share-based payments reserve at FY25 against £2.16m of cash admin costs 2026-02-27, Note 15.
  • Chairman departure announced one day before notice of AGM 2026-03-09.
  • Auditor name reported incorrectly in AGM result and replaced next business day 2026-04-02.
  • "AI" branding is a thin layer over a robotic NHS pharmacy + a third-party Vertex AI WhatsApp triage bot; no proprietary AI revenue line.
  • Negligible institutional anchor; reliance on retail / WRAP / ATM placements.

Earnings vs. expectations

There is no consistent track record to assess. The company IPO'd in August 2025 pre-revenue; the first reporting period (FY25, 12m to Aug 2025) was almost entirely pre-trade and recorded a £4.0m loss vs. essentially no published prior consensus 2026-02-27. The H1 2026 interim is the first commercial period: £1.6m revenue, £3.27m loss, with the only quantified prior management benchmark being "monthly pharmacy revenue in excess of £350,000" disclosed in the FY25 release — H1 delivery is broadly consistent with that, though gross margin took until March 2026 to reach the 34% level management considers representative 2026-05-29. Default: not enough data — score 50 on the surprise driver.

Conviction

Conviction: 2 (low).

  • Anchoring my call: (i) very weak balance sheet and serial dilution evidence make it hard to argue the current market cap is fair on existing fundamentals; (ii) the path to pharmacy-level EBITDA breakeven, even at management's own threshold, leaves group-level losses; (iii) governance red flags compound the discount that should be applied.
  • Limiting my conviction: (i) the GLP-1 supply agreements and Runcorn historical run-rate are genuine optionality and could surprise to the upside if marketing spend converts efficiently; (ii) only one half-year of trading exists, so the valuation lens is heavily judgement-driven rather than anchored in a multi-year track record.
Filings consulted · 13

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-05-29Half Year Financial Report2026-05-29_9590889_half-year-financial-report.md0.90
  2. 2026-04-29Acquisition OF Remedi Pharmacy Assets2026-04-29_9542858_acquisition-of-remedi-pharmacy-assets.md0.75
  3. 2026-04-17Placing TO Raise 3M2026-04-17_9524817_placing-to-raise-3m.md0.70
  4. 2026-04-02Result OF Agm Replacement2026-04-02_9505796_result-of-agm-replacement.md0.30
  5. 2026-03-30Result OF Agm2026-03-30_9498322_result-of-agm.md0.30
  6. 2026-03-20Placing And Wrap Retail Offer2026-03-20_9485280_placing-and-wrap-retail-offer.md0.70
  7. 2026-03-09Notice OF Agm And Board Changes2026-03-09_9464392_notice-of-agm-and-board-changes.md0.30
  8. 2026-02-27Final Results2026-02-27_9451802_final-results.md1.00
  9. 2026-02-16Completion OF Acquisition2026-02-16_9431342_completion-of-acquisition.md0.75
  10. 2026-01-05Trading Update2026-01-05_9333694_trading-update.md0.85
  11. 2025-12-04Trading Update And AT The Market Facility2025-12-04_9274561_trading-update-and-at-the-market-facility.md0.72
  12. 2025-10-01Placing TO Raise 400 0002025-10-01_9144588_placing-to-raise-400-000.md0.59
  13. 2025-10-01Acquisition OF Assets From Universal Pharmacy Ltd2025-10-01_9144543_acquisition-of-assets-from-universal-pharmacy-ltd.md0.64

This research note was authored by a large language model after reading 12 regulatory filings published between 2025-10-01 and 2026-05-29. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.